Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.96, $0.10 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $598.1 million versus the consensus estimate of $596.76 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.